The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

Abstract Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jiang
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Prolactinoma Dopamine agonist Cabergoline Bromocriptine Recurrence Meta-analysis Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/017de2a0a1a64c9aa4461a58e0795625
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:017de2a0a1a64c9aa4461a58e0795625
record_format	dspace
spelling	oai:doaj.org-article:017de2a0a1a64c9aa4461a58e07956252021-11-14T12:05:31ZThe recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis10.1186/s12902-021-00889-11472-6823https://doaj.org/article/017de2a0a1a64c9aa4461a58e07956252021-11-01T00:00:00Zhttps://doi.org/10.1186/s12902-021-00889-1https://doaj.org/toc/1472-6823Abstract Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk of prolactinoma following the withdrawal of DAs. Methods Three medical databases, PubMed, EMBASE and Cochrane library, were retrieved up to February, 14, 2021 to identify studies related to recurrence of prolactinoma and withdrawal of DAs. Statistical analyses including meta-analysis, sensitivity analysis, meta-regression, funnel plot and Egger test were performed through software R. Results A total of 3225 studies were retrieved from the three data bases, and 13 studies consisted of 616 patients and 19 arms were finally included in this systematic analysis. There was no significant heterogeneity among the included studies, and fixed effect model was thus used. The pooled recurrence proportion of prolactinoma after withdrawal of DA was 2% with a 95% confidence interval (CI) of 1–3%. Conclusion Our study showed a very low recurrent rate of prolactinomas after DAs withdrawal. Much more prospective studies with larger cases and longer follow-up period are encouraged to confirm our finding. Trial registration Registration number CRD42021245888 (PROSPERO).Yunzhi ZouDepei LiJiayu GuSiyu ChenXia WenJiajun DongXiaobing JiangBMCarticleProlactinomaDopamine agonistCabergolineBromocriptineRecurrenceMeta-analysisDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENBMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Prolactinoma Dopamine agonist Cabergoline Bromocriptine Recurrence Meta-analysis Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Prolactinoma Dopamine agonist Cabergoline Bromocriptine Recurrence Meta-analysis Diseases of the endocrine glands. Clinical endocrinology RC648-665 Yunzhi Zou Depei Li Jiayu Gu Siyu Chen Xia Wen Jiajun Dong Xiaobing Jiang The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
description	Abstract Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk of prolactinoma following the withdrawal of DAs. Methods Three medical databases, PubMed, EMBASE and Cochrane library, were retrieved up to February, 14, 2021 to identify studies related to recurrence of prolactinoma and withdrawal of DAs. Statistical analyses including meta-analysis, sensitivity analysis, meta-regression, funnel plot and Egger test were performed through software R. Results A total of 3225 studies were retrieved from the three data bases, and 13 studies consisted of 616 patients and 19 arms were finally included in this systematic analysis. There was no significant heterogeneity among the included studies, and fixed effect model was thus used. The pooled recurrence proportion of prolactinoma after withdrawal of DA was 2% with a 95% confidence interval (CI) of 1–3%. Conclusion Our study showed a very low recurrent rate of prolactinomas after DAs withdrawal. Much more prospective studies with larger cases and longer follow-up period are encouraged to confirm our finding. Trial registration Registration number CRD42021245888 (PROSPERO).
format	article
author	Yunzhi Zou Depei Li Jiayu Gu Siyu Chen Xia Wen Jiajun Dong Xiaobing Jiang
author_facet	Yunzhi Zou Depei Li Jiayu Gu Siyu Chen Xia Wen Jiajun Dong Xiaobing Jiang
author_sort	Yunzhi Zou
title	The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
title_short	The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
title_full	The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
title_fullStr	The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
title_full_unstemmed	The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
title_sort	recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/017de2a0a1a64c9aa4461a58e0795625
work_keys_str_mv	AT yunzhizou therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT depeili therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT jiayugu therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT siyuchen therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT xiawen therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT jiajundong therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT xiaobingjiang therecurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT yunzhizou recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT depeili recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT jiayugu recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT siyuchen recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT xiawen recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT jiajundong recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis AT xiaobingjiang recurrenceofprolactinomaafterwithdrawalofdopamineagonistasystematicreviewandmetaanalysis
_version_	1718429446455689216

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

Ejemplares similares